Chief Executive Officer - Martin Whitaker

Martin Whitaker, BSc PhD - Chief Executive Officer

Martin Whitaker is Chief Executive Officer of Diurnal with overall responsibility for delivering the Group's commercial objectives. Martin has over 15 years' experience in the pharmaceutical industry and has led the Diurnal team to progress the Company’s lead products, Chronocort® and Infacort®, into pivotal Phase III clinical trials. Martin is also Director of D3 Pharma Limited which has successfully commercialised Plenachol®, a high dose Vitamin D product prescribed in the UK. Previously, Martin worked for Fusion IP plc with responsibility for commercialising research from the Medical School at the University of Sheffield.  Prior to this, Martin was Operations Director of Critical Pharmaceuticals Limited, a venture capital-backed drug delivery company spun out of the University of Nottingham developing long-acting growth hormone products. Martin is a biochemist by background and has a PhD in Pharmaceutical Science from the University of Nottingham and a BSc (Hons) in Biochemistry from Bristol University. Martin also spent a year working for the pharmaceutical company, Pfizer, in Sandwich (UK). He is Honorary Professor of Medical Innovation at The University of Sheffield.

Chief Financial Officer - Richard Bungay

Richard Bungay, BSc ACA - Chief Financial Officer

Richard Bungay is Chief Financial Officer of Diurnal. Richard has over 20 years’ experience in senior finance and strategic roles within the pharmaceutical and biotechnology sector, mostly recently as CFO and COO of Mereo BioPharma, a company focused on developing treatments for rare and specialty diseases. His prior experience includes CFO of Glide Technologies. CFO of Verona Pharma, CEO (formerly CFO) of Chroma Therapeutics, Director of Corporate Communications and Strategic Planning at Celltech and finance director of the Respiratory and Inflammation therapy area at AstraZeneca. He qualified as a chartered accountant with Deloitte and has a first class degree in Chemistry from Nottingham University. Mr Bungay is a non-executive director of Glide Technologies. 

Chief Scientific Officer - Richard Ross

Richard Ross, MBBS MD FRCP - Chief Scientific Officer

Richard Ross is a founding Director of Diurnal and Chief Scientific Officer and is contracted to perform work for the Group by the University pursuant to the terms of a secondment agreement and a research agreement. He is a Professor of Clinical Endocrinology and Head of the Academic Unit of Diabetes, Endocrinology and Metabolism at the University of Sheffield and was previously a Senior Lecturer at St. Bartholomew’s Hospital, London. Richard’s primary research interest is pituitary and adrenal disease with a particular focus on hormone replacement. His research has yielded over 200 papers, more than 30 granted patents and publications in Nature Medicine, Nature Reviews Endocrinology, Nature Genetics, The Lancet, The BMJ and PNAS. He has been a member of the editorial boards of Clinical Endocrinology and the Journal of Clinical Endocrinology and Metabolism and served as an elected member of the executive committees for the European Society of Endocrinology (Treasurer), the Society for Endocrinology and Growth Hormone Research Society.

Commercial Director - Michael Withe

Michael Withe - Commercial Director

Michael Withe is Commercial Director at Diurnal with responsibility for delivering the Group’s commercial objectives. Michael has over 20 years’ experience in the pharmaceutical industry specifically Orphan Drugs and Speciality pharmaceuticals. Previously, Michael worked for Chiesi as Head of Rare Diseases with responsibility for the creation of the Global Rare Disease Franchise and commercialising the first gene therapy and Limbus Stem Cell transplantation in the western world. Prior to this, Michael worked in the area of Lysosomal Storage Disorders for Shire and BioMarin. Michael is a microbiologist by background with a postgraduate qualification in marketing.

Medical Affairs Director - John Porter

John Porter, MBBS PhD - Medical Affairs Director 

John Porter is Medical Affairs Director at Diurnal. John is a paediatric endocrinologist and has 11 years’ experience in the pharmaceutical industry. Previously, John had medical director roles at Pfizer, Novartis and GSK covering a wide portfolio of medicines in therapy areas including endocrinology, haematology, infectious disease and vaccines. John studied medicine at Oxford and Newcastle-upon-Tyne Universities, qualifying in 1995. He trained in paediatric endocrinology and diabetes and has a PhD in the genetics of paediatric diabetes.

Medical Director - Madhu Davies

Madhu Davies, MB ChB MRCGP FFPM MBA - Medical Director

Madhu has over 20 years’ experience with a range of pharmaceutical and biotechnology companies. She has supported the development and launch of a wide range of products in all the major markets and has been involved in the in-licensing and out-licensing of projects both in the large pharma and biotech settings.  She is also a Non-Executive Director of a public sector organisation and provides direction to the Postgraduate Course in Pharmaceutical Medicine (Cardiff University/British Association of Pharmaceutical Physicians). Madhu qualified in medicine from Birmingham University, she is a member of the Royal College of General Practitioners, a Fellow of the Faculty of Pharmaceutical Medicine and has an MBA from the Judge Business School, University of Cambridge. Madhu joined Diurnal in 2016.

CMC Director - Daniel Margetson

Daniel Margetson, PhD - CMC Director 

Daniel Margetson is Director of Chemistry, Manufacturing & Controls with responsibility for managing the CMC development activities for Diurnal’s programmes. Daniel brings 20 years of pharmaceutical experience in Research & Development, Commercial Supply Chain and Strategic Collaborations roles. Prior to joining Diurnal, Daniel worked at Shire Pharmaceuticals contributing to the development and globalisation of Vyvanse® and managing commercial supply chain for Lialda® and Pentasa®, at Eisai, he supported the transfer of Aricept® commercial production from Japan to the UK. Daniel worked at GlaxoSmithKline for 13 years across all phases of product development and was instrumental in developing several patented drug delivery technologies that were sold or commercialised. Daniel is experienced operating in a virtual business environment, managing CDMOs in the UK, US, Europe and India. Daniel holds a PhD in Pharmaceutics from Queen’s University Belfast and a degree in Pharmaceutical Sciences from the University of Greenwich, London. He is a member of the UK and Ireland Controlled Release Society and the Royal Society of Chemistry.